Lead Focus Lead immunotherapy program CTX-187 in Phase I candidates presents an early engagement opportunity for BD teams to discuss collaboration or co-development options around Alphamer platform applications in infectious disease.

Strategic Funding Recent Series A extensions and multi-million (£6M+) funding from AMR Action Fund indicate investor confidence and potential appetite for partner-driven milestone-based deals or contract research opportunities to accelerate clinical milestones.

Antibody Recruiting Alphamer technology re-directs existing antibodies to pathogens, offering a unique angle for partners in diagnostics, therapeutic antibody development, or combination therapies seeking to enhance immune engagement and rapid infection clearance.

Clinical Momentum Active progression toward human trials in ABX-01 programme with a first clinical candidate launched in 2025 signals readiness for strategic partnerships, licensing, or sponsored research for later-stage development.

Biotech Footprint Allderley Park UK-based biotech with a modest team size and a clear IP-protected platform; potential for regional collaborations, CRO partnerships, and access to early-stage discovery services for antimicrobial programs.